The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global HER-2 Targeted Drugs for Breast Cancer Market Research Report 2025
Synopsis
The global HER-2 Targeted Drugs for Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for HER-2 Targeted Drugs for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER-2 Targeted Drugs for Breast Cancer.
Report Scope
The HER-2 Targeted Drugs for Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HER-2 Targeted Drugs for Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HER-2 Targeted Drugs for Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Chugai Pharmaceutical
GlaxoSmithKline
Novartis
Pfizer
CANbridge
Puma Biotechnology
Hengrui Medicine
Beacon Pharmaceuticals Limited
Hetero Drugs
Segment by Type
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Others
Segment by Application
Hospital
Clinic
Drug Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HER-2 Targeted Drugs for Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global HER-2 Targeted Drugs for Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for HER-2 Targeted Drugs for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER-2 Targeted Drugs for Breast Cancer.
Report Scope
The HER-2 Targeted Drugs for Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HER-2 Targeted Drugs for Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HER-2 Targeted Drugs for Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Chugai Pharmaceutical
GlaxoSmithKline
Novartis
Pfizer
CANbridge
Puma Biotechnology
Hengrui Medicine
Beacon Pharmaceuticals Limited
Hetero Drugs
Segment by Type
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Others
Segment by Application
Hospital
Clinic
Drug Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HER-2 Targeted Drugs for Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Trastuzumab
1.2.3 Pertuzumab
1.2.4 Lapatinib
1.2.5 Neratinib
1.2.6 Trastuzumab Emtansine
1.2.7 Pyrotinib
1.2.8 Others
1.3 Market by Application
1.3.1 Global HER-2 Targeted Drugs for Breast Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Perspective (2019-2030)
2.2 HER-2 Targeted Drugs for Breast Cancer Growth Trends by Region
2.2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Region (2019-2024)
2.2.3 HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2025-2030)
2.3 HER-2 Targeted Drugs for Breast Cancer Market Dynamics
2.3.1 HER-2 Targeted Drugs for Breast Cancer Industry Trends
2.3.2 HER-2 Targeted Drugs for Breast Cancer Market Drivers
2.3.3 HER-2 Targeted Drugs for Breast Cancer Market Challenges
2.3.4 HER-2 Targeted Drugs for Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Revenue
3.1.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Revenue (2019-2024)
3.1.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Players (2019-2024)
3.2 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HER-2 Targeted Drugs for Breast Cancer Revenue
3.4 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio
3.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HER-2 Targeted Drugs for Breast Cancer Revenue in 2023
3.5 HER-2 Targeted Drugs for Breast Cancer Key Players Head office and Area Served
3.6 Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
3.7 Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HER-2 Targeted Drugs for Breast Cancer Breakdown Data by Type
4.1 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Type (2019-2024)
4.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2025-2030)
5 HER-2 Targeted Drugs for Breast Cancer Breakdown Data by Application
5.1 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Application (2019-2024)
5.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size (2019-2030)
6.2 North America HER-2 Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
6.4 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size (2019-2030)
7.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
7.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size (2019-2030)
8.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size (2019-2030)
9.2 Latin America HER-2 Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
9.4 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size (2019-2030)
10.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Introduction
11.1.4 Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Chugai Pharmaceutical
11.2.1 Chugai Pharmaceutical Company Detail
11.2.2 Chugai Pharmaceutical Business Overview
11.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Introduction
11.2.4 Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.2.5 Chugai Pharmaceutical Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Introduction
11.3.4 GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Introduction
11.4.4 Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Introduction
11.5.4 Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 CANbridge
11.6.1 CANbridge Company Detail
11.6.2 CANbridge Business Overview
11.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Introduction
11.6.4 CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.6.5 CANbridge Recent Development
11.7 Puma Biotechnology
11.7.1 Puma Biotechnology Company Detail
11.7.2 Puma Biotechnology Business Overview
11.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Introduction
11.7.4 Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.7.5 Puma Biotechnology Recent Development
11.8 Hengrui Medicine
11.8.1 Hengrui Medicine Company Detail
11.8.2 Hengrui Medicine Business Overview
11.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Introduction
11.8.4 Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.8.5 Hengrui Medicine Recent Development
11.9 Beacon Pharmaceuticals Limited
11.9.1 Beacon Pharmaceuticals Limited Company Detail
11.9.2 Beacon Pharmaceuticals Limited Business Overview
11.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Introduction
11.9.4 Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.9.5 Beacon Pharmaceuticals Limited Recent Development
11.10 Hetero Drugs
11.10.1 Hetero Drugs Company Detail
11.10.2 Hetero Drugs Business Overview
11.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Introduction
11.10.4 Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
11.10.5 Hetero Drugs Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Trastuzumab
Table 3. Key Players of Pertuzumab
Table 4. Key Players of Lapatinib
Table 5. Key Players of Neratinib
Table 6. Key Players of Trastuzumab Emtansine
Table 7. Key Players of Pyrotinib
Table 8. Key Players of Others
Table 9. Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Region (2019-2024)
Table 13. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Region (2025-2030)
Table 15. HER-2 Targeted Drugs for Breast Cancer Market Trends
Table 16. HER-2 Targeted Drugs for Breast Cancer Market Drivers
Table 17. HER-2 Targeted Drugs for Breast Cancer Market Challenges
Table 18. HER-2 Targeted Drugs for Breast Cancer Market Restraints
Table 19. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Players (2019-2024)
Table 21. Global Top HER-2 Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2023)
Table 22. Ranking of Global Top HER-2 Targeted Drugs for Breast Cancer Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by HER-2 Targeted Drugs for Breast Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
Table 26. Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type (2019-2024)
Table 30. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type (2025-2030)
Table 32. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application (2019-2024)
Table 34. Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application (2025-2030)
Table 36. North America HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 51. Roche Company Detail
Table 52. Roche Business Overview
Table 53. Roche HER-2 Targeted Drugs for Breast Cancer Product
Table 54. Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 55. Roche Recent Development
Table 56. Chugai Pharmaceutical Company Detail
Table 57. Chugai Pharmaceutical Business Overview
Table 58. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product
Table 59. Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 60. Chugai Pharmaceutical Recent Development
Table 61. GlaxoSmithKline Company Detail
Table 62. GlaxoSmithKline Business Overview
Table 63. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product
Table 64. GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 65. GlaxoSmithKline Recent Development
Table 66. Novartis Company Detail
Table 67. Novartis Business Overview
Table 68. Novartis HER-2 Targeted Drugs for Breast Cancer Product
Table 69. Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Pfizer Company Detail
Table 72. Pfizer Business Overview
Table 73. Pfizer HER-2 Targeted Drugs for Breast Cancer Product
Table 74. Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 75. Pfizer Recent Development
Table 76. CANbridge Company Detail
Table 77. CANbridge Business Overview
Table 78. CANbridge HER-2 Targeted Drugs for Breast Cancer Product
Table 79. CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 80. CANbridge Recent Development
Table 81. Puma Biotechnology Company Detail
Table 82. Puma Biotechnology Business Overview
Table 83. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product
Table 84. Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 85. Puma Biotechnology Recent Development
Table 86. Hengrui Medicine Company Detail
Table 87. Hengrui Medicine Business Overview
Table 88. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product
Table 89. Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 90. Hengrui Medicine Recent Development
Table 91. Beacon Pharmaceuticals Limited Company Detail
Table 92. Beacon Pharmaceuticals Limited Business Overview
Table 93. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product
Table 94. Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 95. Beacon Pharmaceuticals Limited Recent Development
Table 96. Hetero Drugs Company Detail
Table 97. Hetero Drugs Business Overview
Table 98. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product
Table 99. Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 100. Hetero Drugs Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HER-2 Targeted Drugs for Breast Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Type: 2023 VS 2030
Figure 3. Trastuzumab Features
Figure 4. Pertuzumab Features
Figure 5. Lapatinib Features
Figure 6. Neratinib Features
Figure 7. Trastuzumab Emtansine Features
Figure 8. Pyrotinib Features
Figure 9. Others Features
Figure 10. Global HER-2 Targeted Drugs for Breast Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application: 2023 VS 2030
Figure 12. Hospital Case Studies
Figure 13. Clinic Case Studies
Figure 14. Drug Center Case Studies
Figure 15. Others Case Studies
Figure 16. HER-2 Targeted Drugs for Breast Cancer Report Years Considered
Figure 17. Global HER-2 Targeted Drugs for Breast Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global HER-2 Targeted Drugs for Breast Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Region: 2023 VS 2030
Figure 20. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Players in 2023
Figure 21. Global Top HER-2 Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by HER-2 Targeted Drugs for Breast Cancer Revenue in 2023
Figure 23. North America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America HER-2 Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 25. United States HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe HER-2 Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 29. Germany HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Share by Region (2019-2030)
Figure 37. China HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America HER-2 Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 45. Mexico HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 49. Turkey HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Roche Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 52. Chugai Pharmaceutical Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 53. GlaxoSmithKline Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 54. Novartis Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 56. CANbridge Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 57. Puma Biotechnology Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 58. Hengrui Medicine Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 59. Beacon Pharmaceuticals Limited Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 60. Hetero Drugs Revenue Growth Rate in HER-2 Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
